Haemonetics (HAE) EBIT Margin (2009 - 2026)

Haemonetics has reported EBIT Margin for 18 years, with the latest figure at 16.93% in Q2 2026.

• On a quarterly basis, EBIT Margin rose 17.0% year-over-year to 16.93% in Q2 2026; TTM through Jun 2026 was 11.86%, a 567.0% decrease from a year earlier, with the FY2026 full-year figure at 11.75%, down 455.0% from the prior year.
• EBIT Margin was 16.93% for Q2 2026 at Haemonetics, up from 6.65% in the prior quarter.
• The five-year high for EBIT Margin was 21.58% in Q1 2025, with the low at 6.65% in Q1 2026.
• Average EBIT Margin over 5 years is 13.42%, with a median of 14.18% recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EBIT Margin surged 1665 bps in 2022, then plunged 2823 bps in 2026.
• Over 5 years, EBIT Margin stood at 14.18% in 2022, then slipped by 4 bps to 13.67% in 2023, then advanced by 24 bps to 16.94% in 2024, then increased by 17 bps to 19.88% in 2025, then dropped by 15 bps to 16.93% in 2026.
• The last three EBIT Margin figures came in at 16.93% (Q2 2026), 6.65% (Q1 2026), and 19.88% (Q4 2025), per Business Quant data.